NIKKEI 225
36,877.67 -1,202.03 (-3.16%) HANG SENG
16,098.56 -287.31 (-1.75%) CRUDE OIL
85.64 +2.91 (+3.52%) GOLD FUTURES
2,428.50 +30.50 (+1.27%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,291.80 -349.36 (-0.70%)
NeuroSense Therapeutics Ltd. (NRSN)
After hours:
| Previous close | 1.6000 |
| Open | 1.5900 |
| Bid | 1.4500 x 200 |
| Ask | 1.5500 x 100 |
| Day's range | 1.4600 - 1.6200 |
| 52-week range | 0.4000 - 2.3300 |
| Volume | |
| Avg. volume | 313,970 |
| Market cap | 26.348M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. In addition to the positive clinical outcomes, the study also demonstrated a positive trend toward impa
- PR Newswire
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.
- PR Newswire
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent priv
